EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase...
EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...
4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet...
EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...
EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...
Company to highlight 4D-150 product development strategy and Phase 1/2 PRISM clinical trial data in wet...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.